Montreal Protocol eliminated. This included a 10-year phase-in for developing countries identified in Article 5 of the treaty. The stated purpose of the treaty is that the signatory states "Recognizing that worldwide emissions of certain substances can significantly deplete and otherwise modify the ozone layer in a manner that is likely to result in adverse effects on human health and the environment. Determined to protect the ozone layer by taking precautionary measures to control equitably total global emissions of substances that deplete it with the ultimate objective of their elimination on the basis of developments in scientific knowledge" "Acknowledging that special provision
Wiley protocol at separate times throughout the period. The protocol is promoted as differing from conventional hormone replacement therapy in several ways: The protocol also includes a follow-up program to monitor the serum of the bioidentical hormones. Wiley has stated that in her opinion, the most important aspect of the protocol is the specific schedule and levels of the hormone doses rather than their bioidentical nature. A patent was granted for the protocol in 2011 for the specific blend of hormones and dosing method. Concerns have been raised that serum levels may not be an acceptable marker for transdermally administered hormones, that